Octarine is a synthetic biology company developing biosynthetic platforms for cannabinoids, psychedelics and their novel improved derivatives.
Octarine’s mission is to solve our greatest health challenges by enabling innovative cannabinoid and psychedelic therapeutics.
Octarine was founded in September 2018 by Nethaji Gallage and Nick Milne. The company is headquartered in Frederiksberg, Copenhagen, Denmark.
Octarine brings together genetic elements from across the natural world to deliver new bioactive molecules beyond the reach of nature or man-made techniques, providing blue ocean market opportunities to our partners and customers.
Octarine’s core programs focus on perfecting novel, and improved cannabinoids and bioactive tryptamines a for a range of applications within human and planetary health.
Octarine's proprietary technology combines synthetic biology, yeast fermentation and enzymatic derivatization to develop IP protected drug candidates that are validated in pre-clinical models.
Octarine is backed by DSM Venturing, Danish State Growth Fund (Vækstfonden), Enexis AB, Oskare Capital, Bruce Linton, and others. The company closed a €2M pre-Series A round on Sep 20, 2022. This brings Octarine's total funding to $5M to date.